NorthLinks Bio Launches with $34 Million Financing from RA Capital Management
NorthLinks Bio, a clinical-stage biotechnology company reorganized from UK-based Pneumagen Ltd., has secured $34 million in financing led by RA Capital Management. The funds will advance HEX17, its lead intranasal antiviral candidate for respiratory infections, toward Phase 2b readiness and support US operations.
Topics: antiviral drug development company reorganization financing phase 2b clinical trials